Literature DB >> 453473

Hypercalcemia and malignant melanoma.

M E Burt, M F Brennan.   

Abstract

Malignant melanoma occurs in approximately 1.7 per cent of all patients admitted to the Clinical Center, National Institutes of Health, and approximately 1.8 per cent of patients admitted with hypercalcemia and malignant disease. The incidence of hypercalcemia and malignant melanoma is 1.1 per cent. Bone metastases are diagnosed before death in approximately 5.2 per cent of patients with malignant melanoma. The cause of hypercalcemia in our patients appears to be bone metastases in 83.3 per cent and primary hyperparathyroidism in 16.9 per cent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 453473     DOI: 10.1016/0002-9610(79)90095-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Serum calcium, albumin and tumor stage in cutaneous malignant melanoma.

Authors:  Mridul Datta; Paul Savage; James Lovato; Gary G Schwartz
Journal:  Future Oncol       Date:  2016-06-16       Impact factor: 3.404

2.  Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.

Authors:  Peter Attia; Giao Q Phan; Paul H Duray; Steven A Rosenberg
Journal:  Am J Clin Oncol       Date:  2003-02       Impact factor: 2.339

3.  Complications of bone metastases from malignant melanoma.

Authors:  Jamal Zekri; Maria Marples; Dominic Taylor; Kiran Kandukurti; Lucy McParland; Janet E Brown
Journal:  J Bone Oncol       Date:  2017-08-18       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.